Table F-4Network analysis excluding trials judged to have included women without vasomotor symptoms (n=136); SMD and 95% credible interval

E-High
0.03 (-0.10 to 0.16)E-Standard
-0.08 (-0.22 to 0.06)-0.11 (-0.20 to -0.02)E-Low/Ultralow
-0.23 (-0.43 to -0.04)-0.26 (-0.42 to -0.09)-0.15 (-0.31 to 0.01)SSRI/SNRI
-0.28 (-0.53 to -0.02)-0.31 (-0.54 to -0.08)-0.20 (-0.42 to 0.03)-0.05 (-0.31 to 0.21)Gabapentin
-0.27 (-0.44 to -0.10)-0.29 (-0.43 to -0.16)-0.18 (-0.31 to -0.06)-0.04 (-0.21 to 0.14)0.01 (-0.23 to 0.25)Isoflavones
-0.36 (-0.62 to -0.11)-0.39 (-0.62 to -0.17)-0.28 (-0.50 to -0.06)-0.13 (-0.39 to 0.13)-0.08 (-0.39 to 0.22)-0.10 (-0.34 to 0.15)Black Cohosh
-0.41 (-0.75 to -0.07)-0.44 (-0.77 to -0.11)-0.33 (-0.65 to -0.00)-0.18 (-0.53 to 0.17)-0.13 (-0.52 to 0.25)-0.14 (-0.48 to 0.19)-0.05 (-0.43 to 0.34)Ginseng
-0.61 (-0.74 to -0.47)-0.63 (-0.71 to -0.55)-0.52 (-0.59 to -0.46)-0.38 (-0.52 to -0.23)-0.33 (-0.55 to -0.11)-0.34 (-0.44 to -0.24)-0.24 (-0.46 to -0.03)-0.20 (-0.51 to 0.12)Placebo

From: Appendix F, Vasomotor Symptom Supplemental Tables and Plots

Cover of Menopausal Symptoms: Comparative Effectiveness of Therapies
Menopausal Symptoms: Comparative Effectiveness of Therapies [Internet].
Comparative Effectiveness Reviews, No. 147.
Grant MD, Marbella A, Wang AT, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.